Markets:

Overview

News

Currencies

International

Treasuries

State Street SPDR S&P Biotech ETF (NY:XBI)

152.09 +1.62 (+1.07%)

Streaming Delayed Price Updated: 3:18 PM EDT, Jul 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about State Street SPDR S&P Biotech ETF

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Here's How Much $100 Invested In State Street SPDR S&P Biotech ETF 20 Years Ago Would Be Worth Today ↗

July 13, 2026

State Street SPDR S&P Biotech ETF (NYSE:XBI) has outperformed the market over the past 20 years by 3.16% on an annualized basis producing an average annual return of 12.55%. Currently, State Street...

Via Benzinga

Topics ETFs Stocks

Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026? ↗

July 09, 2026

PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost.

Via The Motley Fool

Topics ETFs

Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best? ↗

July 05, 2026

One offers broad stability with lower costs and higher income, while the other chases biotech growth with 89.3% annual returns but steeper volatility.

Via The Motley Fool

Topics ETFs

The Best Biotech Stocks to Buy in 2026 ↗

June 17, 2026

They have at least one thing in common: An exciting pipeline.

Via The Motley Fool

Topics ETFs

Is iShares Pharma ETF (IHE) or SPDR's Biotech ETF (XBI) the Better Long-Term Buy for Investors? ↗

June 17, 2026

Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to growth and stability.

Via The Motley Fool

Topics ETFs

3 Longevity ETFs to Buy and Hold (and Hold) ↗

June 08, 2026

The size of the longevity industry could roughly triple in the next decade, and these ETFs may help to provide access to a fast-growing space.

Via MarketBeat

Topics Artificial Intelligence ETFs

Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech ↗

June 05, 2026

Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.

Via The Motley Fool

Topics ETFs

VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost ↗

May 28, 2026

Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare.

Via The Motley Fool

Topics ETFs

2 Ways to Play the Big Pharma Patent Cliff ↗

May 15, 2026

With hundreds of billions in sales on the line for drugs that will lose their patent exclusivity in the coming years, two biotech ETFs can help capitalize.

Via MarketBeat

Topics ETFs Intellectual Property

Small Caps Under Siege: Russell 2000 Enters Correction as Yields Surge

March 23, 2026

The small-cap segment of the U.S. stock market has officially entered correction territory, marking a stark reversal for a sector that many analysts expected to lead the "Great Rotation" of 2026. On...

Via MarketMinute

Topics Bonds ETFs Economy

DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing ↗

March 21, 2026

iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...

Via The Motley Fool

Topics Derivatives ETFs Regulatory Compliance

IBRX Stock Rises Overnight: Retail Bets Anktiva’s NCCN 'Recommended' Tag Will Drive Prescriptions And Insurance Wins ↗

March 17, 2026

Users highlighted that NCCN inclusion could lead to increased prescribing of Anktiva by oncologists and improved insurance reimbursement.

Via Stocktwits

Topics ETFs

The Azetukalner Breakthrough: A Deep Dive into Xenon Pharmaceuticals (XENE)

March 12, 2026

Date: March 12, 2026Sector: Biotechnology / NeurologyMarket Cap: ~$4.8 Billion Introduction On March 9, 2026, the neurology sector of the biotechnology market witnessed a seismic shift. Xenon...

Via Finterra

Topics ETFs Intellectual Property

Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? ↗

March 11, 2026

Watcher count for PLYX on Stocktwits increased by nearly 50% in a single day.

Via Stocktwits

Topics ETFs

QURE Stock Edges Up After Hours As Analyst Flags Reduced Regulatory Uncertainty Following Prasad’s FDA Exit ↗

March 10, 2026

Mizuho said that Dr. Vinay Prasad’s exit just days after a highly public dispute with uniQure appeared to signal an administration-level desire to restore greater regulatory flexibility in rare disease...

Via Stocktwits

QURE Stock’s Relentless Rally Continues Today — Here's Why HC Wainwright Is Bullish On uniQure ↗

March 10, 2026

H.C. Wainwright stated that the reported departure of a key U.S. Food and Drug Administration official at the end of April bodes well for uniQure.

Via Stocktwits

Topics Initial Public Offering

QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 ↗

March 09, 2026

Wells Fargo upgraded uniQure’s stock to ‘Overweight,’ citing a bullish outlook for its gene therapy following reports that Vinay Prasad will leave the U.S. FDA next month.

Via Stocktwits

IBRX Stock Declines Pre-Market — ImmunityBio Resubmits Anktiva Application To FDA With Additional Data ↗

March 09, 2026

ImmunityBio stated that the application includes additional information requested by the FDA to support its supplemental BLA for papillary disease.

Via Stocktwits

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗

March 05, 2026

CFO says company continues to be “strategic and opportunistic” in approach to securing capital needed for late-stage MASH trial.

Via Stocktwits

Why Did CRMD Stock Tumble Over 11% Today? ↗

March 05, 2026

The company reported mixed Q4 results with a revenue of $128.6 million and earnings per share of $0.16.

Via Stocktwits

Topics Artificial Intelligence

Why Did BTAI Stock Surge 20% In Pre-Market Today? ↗

March 05, 2026

BioXcel announced positive Phase 2 results for evaluating treatment for opioid withdrawal symptoms.

Via Stocktwits

Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth ↗

March 05, 2026

Product revenue from YUTREPIA reached approximately $148.3 million in 2025, including about $90.1 million generated during the fourth quarter alone.

Via Stocktwits

Topics Artificial Intelligence

DAWN Shares Rally On Buyout Speculation But Retail Warns A Deal Might Not Materialise ↗

March 04, 2026

On Stocktwits, retail sentiment around DAWN stock stayed within the ‘extremely bullish’ territory over the past 24 hours.

Via Stocktwits

Topics Economy

IBRX Stock Drops On Investor Concerns Over Immunotherapy Launch In Saudi Arabia Amid Middle East Tensions But Analyst Sees 20% Upside ↗

March 04, 2026

Piper Sandler raised the firm's price target on ImmunityBio to $12 from $7 and kept an ‘Overweight’ rating on the shares.

Via Stocktwits

Topics Intellectual Property

Why Did NTLA Stock Jump 10% In Pre-Market Today? ↗

March 02, 2026

The company announced that the U.S. FDA lifted a clinical hold on its Phase 3 trial of ATTR-CM treatment drug.

Via Stocktwits

Why Did QURE Stock Almost Halve Pre-Market Today? ↗

March 02, 2026

uniQure said the FDA does not agree that Phase I/II data are sufficient to serve as primary evidence of effectiveness for a marketing application for its Huntington’s disease gene therapy, AMT-130.

Via Stocktwits

AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction ↗

February 26, 2026

The company said on Thursday that it now expects its mid-stage trial of AKB-097 in rare kidney diseases to start in the second half of 2026, with initial data expected in 2027.

Via Stocktwits

IBRX Stock Rises Pre-Market After ANKTIVA Combo Shows Stronger Bladder Cancer Responses In Phase 2 Trial ↗

February 26, 2026

The company said it plans to submit a biologics license application by the fourth quarter of 2026.

Via Stocktwits

CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent ↗

February 25, 2026

The company said it has enrolled patients in its late-stage program ahead of schedule.

Via Stocktwits

Topics Earnings

RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ ↗

February 25, 2026

Recursion reported a loss of $0.21 per share on revenue of $35.5 million, compared to Wall Street estimates of a loss of $0.32 per share on revenue of $24.6 million, according to Koyfin.

Via Stocktwits

Topics Artificial Intelligence

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.